Beloteca, Inc. Opens Product Development Laboratory In San Diego, California
10/28/2015
According to company officials, “Beloteca's primary focus is to develop and obtain regulatory approval for sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. We target niche and difficult to manufacture products.”
"This new laboratory helps Beloteca achieve its mission of developing multiple products per year," said Fred Defesche, CEO of Beloteca, Inc. "It also allows Beloteca to take greater control over project timelines and the development process."
"The new laboratory establishes Beloteca's in-house product development capabilities allowing the evaluation of development projects prior to initiating full development creating a more nimble and aggressive approach to project selection. Additionally, the new laboratory will be used for many of Beloteca's analytical and formulation development activities enabling Beloteca to develop many of its products in house," stated Dorla Mirejovsky, CFO of Beloteca.
Project Announcements
Mercedes-Benz Expands Atlanta, Georgia, Operations
05/28/2025
Japan-Based Ohashi Technica U.S.A. Manufacturing Expands Sanbury, Ohio, Production Operations
05/28/2025
Green Fuels Plans Acadia Parish, Louisiana, Operations
05/28/2025
Canada-Based AVL Manufacturing Plans Charlotte, North Carolina, Manufacturing Operations
05/27/2025
SJ Incorporation Plans Cascade, Maryland, Production Operations
05/27/2025
Timberlab Plans Millersburg, Oregon, Manufacturing Operations
05/27/2025
Most Read
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024